B
Barry R. Davis
Researcher at University of Texas at Austin
Publications - 351
Citations - 50989
Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial
John C. Wood,Sara L. Pressel,Zora R. Rogers,Isaac Odame,Janet L. Kwiatkowski,Margaret T. Lee,William Owen,Alan R. Cohen,Timothy G. St. Pierre,Matthew M. Heeney,William H. Schultz,Barry R. Davis,Russell E. Ware +12 more
TL;DR: In this paper, the authors report baseline results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients.
Journal ArticleDOI
ALLHAT: still providing correct answers after 7 years.
Paula T. Einhorn,Barry R. Davis,Jackson T. Wright,Mahboob Rahman,Paul K. Whelton,Sara L. Pressel +5 more
TL;DR: The totality of evidence re-affirms the initial ALLHAT conclusion that thiazide and similar diuretics (at evidence-based doses) are the preferred first-step therapy in most patients with hypertension.
Journal ArticleDOI
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials
Dexter Canoy,Emma Copland,Milad Nazarzadeh,Rema Ramakrishnan,Ana-Catarina Pinho-Gomes,Abdul Salam,Jamie P. Dwyer,Farshad Farzadfar,Johan Sundström,Mark Woodward,Barry R. Davis,Kazem Rahimi +11 more
TL;DR: It is suggested that BP-lowering pharmacotherapy is effective in lowering BP, up to 4 years on average, in people with different characteristics, and Appropriate treatment strategies are needed to sustain substantive long-term BP reductions.
Journal ArticleDOI
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Amy I. Lynch,John H. Eckfeldt,Barry R. Davis,Charles E. Ford,Eric Boerwinkle,Catherine Leiendecker-Foster,Donna K. Arnett +6 more
TL;DR: Evidence is provided that it may be possible to use gene panel scores as a tool to better assess antihypertensive treatment choices to reduce CHD risk in hypertensive individuals.
Journal ArticleDOI
Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.
Amy I. Lynch,Marguerite R. Irvin,Barry R. Davis,Charles E. Ford,John H. Eckfeldt,Donna K. Arnett +5 more
TL;DR: This research contributes to the understanding of the genetic basis of TRH, and further genetic studies ofTRH may help reach the goal of better clinical outcomes for hypertensive patients.